Breast Cancer Clinical Trials in Illinois

Showing 181-200 of 675 trials

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

NCT03367572

This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.

Breast Carcinoma

University of Rochester NCORP Research Base1,363 participantsStarted Apr 2018

Honolulu, Hawaii, United States • Decatur, Illinois, United States • New Orleans, Louisiana, United States +15 more locations

COMPLETEDPhase 1125 miles

A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

NCT04647487

The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.

Breast Cancer

Eli Lilly and Company87 participantsStarted Apr 2021

Atlanta, Georgia, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +16 more locations

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

Breast Cancer Trials in Other Cities

Mirai-MRI: Validation of AI Models for Breast Cancer Risk

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

A Study of PF-06873600 in People With Cancer

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Other Conditions in Illinois